IBD: More Patients on Vedolizumab vs Anti-TNFs at 2 Years IBD: More Patients on Vedolizumab vs Anti-TNFs at 2 Years

Vedolizumab showed a higher overall 1- and 2-year persistence of use compared with two anti –tumor necrosis factor inhibitors in both Crohn ' s disease and ulcerative colitis.MDedge News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news